Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins

As one of the most recognized and well-known drugs for hepatocellular carcinoma (HCC), the antitumor effect of sorafenib against HCC remains to be improved. Bufalin has displayed an antitumor effect in HCC; however, whether the enhanced antitumor effect may be generated with their combined treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haiyong, Zhang, Chenyue, Chi, Huiying, Meng, Zhiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983987/
https://www.ncbi.nlm.nih.gov/pubmed/29693132
http://dx.doi.org/10.3892/mmr.2018.8927

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983987/
https://www.ncbi.nlm.nih.gov/pubmed/29693132
http://dx.doi.org/10.3892/mmr.2018.8927

Ejemplares similares